Topic Hub
Tirzepatide: Independent research hub
A focused topic cluster covering Tirzepatide's dual GIP/GLP-1 mechanism, SURMOUNT/SURPASS trial evidence, safety profile and regulatory status.
- Articles
- 16
- Last updated
- May 2026
- Coverage
- Mechanism · Evidence · Safety · Regulatory
Compound profile
Tirzepatide
Dual GIP/GLP-1 receptor agonist with strong trial evidence for type 2 diabetes and weight management.
Mechanism and biology
How Tirzepatide Works: A Dual GIP/GLP-1 Receptor Agonist
Tirzepatide activates both GIP and GLP-1 receptors, a dual-agonist approach that differentiates it from single-receptor peptides.
Read articleDual Agonism Explained: Why Tirzepatide Targets Two Receptors
Dual agonism activates multiple hormonal pathways simultaneously, amplifying metabolic effects beyond single-receptor approaches.
Read articleThe Mechanism of Tirzepatide-Induced Weight Loss
Tirzepatide reduces body weight through appetite suppression, enhanced satiety, altered energy expenditure, and metabolic effects.
Read articleTrial evidence and clinical data
The SURMOUNT Trial Program: Tirzepatide for Weight Management
SURMOUNT trials demonstrated tirzepatide's efficacy and safety for weight management, with results exceeding prior single-agonist comparisons.
Read articleThe SURPASS Trial Program: Tirzepatide for Type 2 Diabetes
SURPASS trials established tirzepatide's efficacy for glycaemic control in type 2 diabetes, with HbA1c reductions exceeding prior GLP-1 agonists.
Read articleTirzepatide Weight Loss Evidence: A Research Review
Comprehensive review of tirzepatide's weight loss efficacy across SURMOUNT trials, mechanistic studies, and real-world observations.
Read articleTirzepatide for Type 2 Diabetes: The Evidence Base
Comprehensive evidence summary of tirzepatide's glycaemic control efficacy, metabolic benefits, and safety in type 2 diabetes.
Read articleTirzepatide Cardiovascular Evidence: What's Known
Current evidence on tirzepatide's cardiovascular effects, including risk factor improvements and ongoing cardiovascular outcome trials.
Read articleAdverse events and safety signals
Tirzepatide Side Effects: Comprehensive Research Review
Detailed analysis of tirzepatide side effects observed in clinical trials, including incidence, severity, management, and tolerability.
Read articleTirzepatide Safety Profile: A Detailed Look
In-depth examination of tirzepatide's safety, including adverse event rates, serious event assessment, and long-term safety considerations.
Read articleTirzepatide and Gastrointestinal Tolerability
Comprehensive examination of gastrointestinal side effects with tirzepatide, their mechanisms, management, and tolerability.
Read articleRegulatory status and approvals
Tirzepatide and the TGA: Australian Approval Status
Current TGA regulatory status of tirzepatide in Australia, approved indications, and regulatory framework.
Read articleTirzepatide Global Regulatory Status
Tirzepatide's regulatory approval status across major jurisdictions including US FDA, EMA, and other regulatory bodies.
Read articleClass and head-to-head comparisons
Tirzepatide vs Semaglutide: A Detailed Head-to-Head
Comprehensive comparison of tirzepatide and semaglutide across mechanism, efficacy, safety, and clinical applications.
Read articleMounjaro vs Zepbound: Same Molecule, Different Indications
Explanation of why tirzepatide has two brand names, their distinct approved indications, and clinical use contexts.
Read article